A promising approach is the deletion of the CISH gene, coding for the negative regulator of IL-15 signaling CIS, which leads to improved NK cell metabolic profile, increased in vivo persistence and anti-tumor function of NK cells [284]. Here, IL15 is linked to in situ carcinoma.